Advanced

Suramin selectively inhibits carcinoma cell growth that is dependent on extracellular polyamines.

Sandgren, Staffan LU and Belting, Mattias LU (2003) In Anticancer Research 23(2B). p.1223-1228
Abstract
Polyamines are necessary for tumour cell growth. Inhibition of endogenous polyamine biosynthesis results in compensatory up-regulation of polyamine uptake. Here, the combined effect of suramin and the polyamine biosynthesis inhibitor alpha-difluoromethylornithine (DFMO) on human carcinoma cell proliferation was studied. Suramin selectively inhibited the growth of tumour cells made dependent on extracellular polyamines by DFMO-treatment. In an animal tumour model, low non-toxic doses of suramin resulted in a 2-fold increase in DFMO tumour growth reduction. Moreover, suramin bound strongly to polyamine-agarose and significantly inhibited polyamine uptake in DFMO-treated cells. Our results indicate that non-toxic doses of suramin augment... (More)
Polyamines are necessary for tumour cell growth. Inhibition of endogenous polyamine biosynthesis results in compensatory up-regulation of polyamine uptake. Here, the combined effect of suramin and the polyamine biosynthesis inhibitor alpha-difluoromethylornithine (DFMO) on human carcinoma cell proliferation was studied. Suramin selectively inhibited the growth of tumour cells made dependent on extracellular polyamines by DFMO-treatment. In an animal tumour model, low non-toxic doses of suramin resulted in a 2-fold increase in DFMO tumour growth reduction. Moreover, suramin bound strongly to polyamine-agarose and significantly inhibited polyamine uptake in DFMO-treated cells. Our results indicate that non-toxic doses of suramin augment tumour growth inhibition by DFMO, and that a combination of these well-studied anticancer drugs may represent an additional strategy for cancer treatment. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
alpha-difluoromethylornithine, carcinoma, polyamine, suramin, proteoglycan
in
Anticancer Research
volume
23
issue
2B
pages
1223 - 1228
publisher
International Institute of Cancer Research
external identifiers
  • wos:000183471600009
  • scopus:0037861867
ISSN
1791-7530
language
English
LU publication?
yes
id
ea901e42-6617-4cc1-a134-94151d32e07e (old id 115776)
date added to LUP
2007-06-26 12:44:42
date last changed
2018-05-29 11:10:22
@article{ea901e42-6617-4cc1-a134-94151d32e07e,
  abstract     = {Polyamines are necessary for tumour cell growth. Inhibition of endogenous polyamine biosynthesis results in compensatory up-regulation of polyamine uptake. Here, the combined effect of suramin and the polyamine biosynthesis inhibitor alpha-difluoromethylornithine (DFMO) on human carcinoma cell proliferation was studied. Suramin selectively inhibited the growth of tumour cells made dependent on extracellular polyamines by DFMO-treatment. In an animal tumour model, low non-toxic doses of suramin resulted in a 2-fold increase in DFMO tumour growth reduction. Moreover, suramin bound strongly to polyamine-agarose and significantly inhibited polyamine uptake in DFMO-treated cells. Our results indicate that non-toxic doses of suramin augment tumour growth inhibition by DFMO, and that a combination of these well-studied anticancer drugs may represent an additional strategy for cancer treatment.},
  author       = {Sandgren, Staffan and Belting, Mattias},
  issn         = {1791-7530},
  keyword      = {alpha-difluoromethylornithine,carcinoma,polyamine,suramin,proteoglycan},
  language     = {eng},
  number       = {2B},
  pages        = {1223--1228},
  publisher    = {International Institute of Cancer Research},
  series       = {Anticancer Research},
  title        = {Suramin selectively inhibits carcinoma cell growth that is dependent on extracellular polyamines.},
  volume       = {23},
  year         = {2003},
}